Latest News and Press Releases

OSE Immunotherapeutics dévoile son plan stratégique 2026 - 2028 axé sur quatre leviers de création de valeur

OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation

OSE Immunotherapeutics annonce un amendement stratégique au partenariat avec AbbVie sur le développement d’ABBV-230 Cet amendement renforce le rôle d’OSE Immunotherapeutics dans le développement...

Strategic Amendment Enhances OSE Immunotherapeutics’ Role in ABBV-230 Development While Preserving AbbVie’s Long-Term Commitment

EXECUTIVE SUMMARY VALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilities core focus on accelerating development of liquid long-acting drug delivery...

Wugen to Present Correlative Data and Long-Term Follow-Up Updates for Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell therapy at the 2025 ASH Annual Meet

Dublin, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The "Bioburden Testing Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering.The Bioburden Testing Market is...

Dublin, Dec. 05, 2025 (GLOBE NEWSWIRE) -- The "Biochips Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering.The Biochips Market is set to expand from...

OTC:LMMY Dr. Marvin Hausman, an esteemed Immunologist and Board-Certified Urological Surgeon. With more than five decades of experience in drug research.

Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer’s disease psychosis...